Stocktoria
NEOGENOMICS INC NEO
Nasdaq · XNAS · stock · Services-Testing Laboratories · website · IPO 2012-12-10
NEOGENOMICS INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 43.2% | 43.9% | 41.3% | 36.9% | 38.6% |
| Operating margin | -15.9% | -13.9% | -18.2% | -30.9% | -24.5% |
| Net margin | -14.9% | -11.9% | -14.9% | -28.3% | -1.7% |
| FCF margin | -3.0% | -5.2% | -5.2% | -19.0% | -18.8% |
| Return on assets | -7.9% | -4.8% | -5.2% | -8.3% | -0.4% |
| Return on equity | -12.9% | -8.7% | -9.3% | -14.5% | -0.8% |
| Debt / equity | 0.41× | 0.60× | 0.57× | — | — |
| Current ratio | 4.26 | 1.98 | 6.20 | 6.73 | 7.81 |
| Revenue growth | 10.1% | 11.6% | 16.1% | 5.2% | 9.0% |
Source: SEC EDGAR filings · CIK 0001077183 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.